Quoin Pharmaceuticals Ltd. Proceeds from Notes Payable
Quoin Pharmaceuticals Ltd. (QNRX) reported Proceeds from Notes Payable of $3.48 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2023-03-15
- Quoin Pharmaceuticals Ltd. proceeds from notes payable for the quarter ending 2021-12-31 was $0.00.
- Quoin Pharmaceuticals Ltd. proceeds from notes payable for the quarter ending 2021-09-30 was $0.00.
- Quoin Pharmaceuticals Ltd. proceeds from notes payable for fiscal 2021 was $3.48M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 6-K 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $3.48M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2022-11-10 | $3.48M 6-K · filed 2022-11-10 | ||
| 2021-06-30 | $3.48M 6-K · filed 2022-08-18 | |||
| 2020-12-31 | $909.98K 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |